Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
SWI SolarWinds Corp
FSPHX Fidelity® Select Health Care Portfolio
UZAPF Flughafen Zuerich AG
SLVO Credit Suisse X-Links Silver Shares Covered Call ETN
ARQQ Arqit Quantum Inc
MA Mastercard Inc
BEN Franklin Resources Inc
REGN Regeneron Pharmaceuticals Inc
PSNL Personalis Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Longeveron Inc., formerly Longeveron LLC, is a clinical stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. Its lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring clinical trials in various indications, including Aging Frailty, Alzheimer's disease (AD), the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS) and hypoplastic left heart syndrome (HLHS). It is developing Lomecel-B as a therapy for Aging Frailty and is being designed to reduce inflammation associated with Aging Frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. It is conducting two multicenter trials in the United States (U.S.)

Postmarket

Last Trade
Delayed
$7.49
0.065 (0.88%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$7.42
Day's Change
-0.97 (-11.56%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
8.60
Day's Low
7.39
Volume
(Light)
Volume:
491,540

10-day average volume:
2,328,843
491,540

FINAL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Longeveron Inc. Investors with LARGE LOSSES to Secure Counsel Before Important November 12 Deadline in Securities Class Action - LGVN

10:45 am ET November 10, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / November 10, 2021 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ:LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company's initial public offering conducted on or about February 12, 2021 (the "IPO" or "Offering"); and/or (2) between February 12, 2021 and August 12, 2021, both dates inclusive (the "Class Period"), of the important November 12, 2021 lead plaintiff deadline.

Image: https://www.accesswire.com/users/newswire/images/672143/image.png

SO WHAT: If you purchased Longeveron securities pursuant and/or traceable to the IPO and/or during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Longeveron class action, go to http://www.rosenlegal.com/cases-register-2157.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Offering documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading, and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Offering documents and defendants made false and/or misleading statements and/or failed to disclose that: (1) Lomecel-B, a cell-based therapy product which is derived from culture-expanded medicinal signaling cells that are sourced from the bone marrow of young healthy adult donors, was not as effective in treating aging frailty as defendants had ledinvestors to believe; (2) accordingly, Lomecel-B's clinical and commercial prospects with respectto aging frailty were overstated; (3) as a result of all the foregoing, Longeveron's financial andbusiness prospects were also overstated; and (4) as a result, defendants' public statements werematerially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Longeveron class action, go to http://www.rosenlegal.com/cases-register-2157.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

lrosen@rosenlegal.com

pkim@rosenlegal.com

cases@rosenlegal.com

www.rosenlegal.com

SOURCE: The Rosen Law Firm, P.A.

View source version on accesswire.com:

https://www.accesswire.com/672143/FINAL-DEADLINE-ROSEN-A-LEADING-INVESTOR-RIGHTS-LAW-FIRM-Encourages-Longeveron-Inc-Investors-with-LARGE-LOSSES-to-Secure-Counsel-Before-Important-November-12-Deadline-in-Securities-Class-Action--LGVN

comtex tracking

COMTEX_396669471/2457/2021-11-10T10:45:30

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.